McCartneyCT, WeisMN, RuppelGL, NayakRP. Residual volume and total lung capacity to assess reversibility in obstructive lung disease. Respir Care, 2016; 61(11):1505–1512.
2.
Ben SaadH, Ben AmorL, Ben MdallaS, GhannouchiI, Ben EssghairM, SfaxiR, et al. The importance of lung volumes in the investigation of heavy smokers. Rev Mal Respir, 2014; 31(1):29–40.
3.
O'DonnellDE, LavenezianaP. Lung hyperinflation in COPD: the impact of pharmacotherapy. Eur Respir Rev, 2006; 15(100):85–89.
4.
O'DonnellDE, SciurbaF, CelliB, MahlerDA, WebbKA, KalbergCJ, KnobilK. Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD. Chest, 2006; 130(3):647–656.
5.
Ben SaadH, Ben Attia SaafiR, RouatbiS, Ben MdellaS, GarroucheA, Hadj MtirA, et al. Which definition to use when defining reversibility of airway obstruction?. Rev Mal Respir, 2007; 24(9):1107–1115.
6.
Ben SaadH, PréfautC, TabkaZ, ZbidiA, HayotM. The forgotten message from GOLD: FVC is a primary clinical outcome measure of bronchodilator reversibility in COPD. Pulm Pharmacol Ther, 2008; 21(5):767–773.
7.
JohannessenA, LehmannS, OmenaasER, EideGE, BakkePS, GulsvikA. Post-bronchodilator spirometry reference values in adults and implications for disease management. Am J Respir Crit Care Med, 2006; 173(12):1316–1325.
8.
Pérez-PadillaR, Torre BouscouletL, Vázquez-GarcíaJC, MuiñoA, MárquezM, LópezMV, et al. [Spirometry reference values after inhalation of 200 microg of salbutamol]. Arch Bronconeumol, 2007; 43(10):530–534.
CelliBR, DecramerM, WedzichaJA, WilsonKC, AgustíA, CrinerGJ, et al. An official American Thoracic Society/European Respiratory Society statement: research questions in COPD. Eur Respir J, 2015; 45(4):879–905.
